Simon Barry J. has sold 25,000 shares of ImmunityBio, Inc. on October 5, 2026. This transaction is part of a Rule 10b5-1 trading plan that Barry adopted on December 18, 2025. The sale was executed at a weighted average price of $10.7504 per share.
This transaction is significant as it reflects ongoing activity from key stakeholders within ImmunityBio, a company focused on biological products. Barry's sale reduces his total ownership to approximately 2.78 million shares.
Background
ImmunityBio, Inc. is a company that specializes in the development of biological products, specifically in the life sciences sector. The company operates under the Central Index Key (CIK) number 0001326110. ImmunityBio was formerly known as NantKwest, Inc. and has undergone several name changes over the years.
What the Filing Says
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.
Impact
This sale may impact investor sentiment regarding ImmunityBio, particularly as it highlights the actions of a significant stakeholder. Barry's status as a director of the company underscores the importance of his transactions in the eyes of investors.
What's Next
The filing does not say what happens next.
Transaction Details
In this transaction, Simon Barry J. sold a total of 25,000 shares of ImmunityBio, Inc. common stock. The sale was executed at a weighted average price of $10.7504 per share, with the actual prices ranging from $10.665 to $10.78. Barry's ownership following this transaction is now approximately 2,777,788 shares.
Ownership Structure
Simon Barry holds a direct ownership stake in ImmunityBio, as indicated by the 'D' designation in the ownership nature section of the filing. As a director of the company, his trading activity is closely monitored by investors and regulatory bodies alike.
Company Information
ImmunityBio, Inc. operates under the Central Index Key (CIK) number 0001326110 and is incorporated in Delaware. The company is classified under the Standard Industrial Classification (SIC) code for Biological Products (No Diagnostic Substances) [2836]. The business address for ImmunityBio is located at 3530 John Hopkins Court, San Diego, CA, 92121.
Legal and Compliance
This filing was submitted in accordance with Section 16 of the Securities Exchange Act of 1934, indicating compliance with the regulations governing insider trading. The transaction was reported on October 6, 2026, reflecting the date of the transaction as October 5, 2026.
Additional Context
The filing does not provide information regarding the specific reasons behind Barry's decision to sell shares or any future plans he may have regarding his remaining holdings in ImmunityBio.